2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

HepG2 liver cells

" in MedChemExpress (MCE) Product Catalog:

58

Inhibitors & Agonists

16

Natural
Products

1

Isotope-Labeled Compounds

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-118224
    BPH-715

    		Parasite Infection
    BPH-715 is a bisphosphonate, inhibits Plasmodium liver-stage growth, with an IC50 of 10 μM for Plasmodium exoerythrocytic forms in HepG2 cells .
    BPH-715
  • HY-169941
    ERα/ERβ antagonist-1

    		Estrogen Receptor/ERR Metabolic Disease Cancer
    ERα/ERβ antagonist-1 (Compound 10) is partial antagonists of ERα and ERβ. ERα/ERβ antagonist-1 reduces ERα and ERβ activity in a dose-dependent manner in HepG2 liver cells .
    ERα/ERβ antagonist-1
  • HY-139140
    BAY R3401

    		Phosphorylase Metabolic Disease
    BAY R3401 is an orally active glycogen phosphorylase inhibitor that can achieve irreversible and non-selective inhibition of hepatic glycogenolysis. BAY R3401 inhibits glycogenolysis in liver cells, with IC50 values of 27.06 and 52.83 μM in HL-7702 and HepG2 cells, respectively. BAY R3401 can be used for the research of type 2 diabetes .
    BAY R3401
  • HY-160059
    JHIT2e aptamer sodium

    		Fluorescent Dye Cancer
    JHIT2e aptamer sodium is a molecular probe based on the aptamer JHIT2 of human liver cancer cell line HepG2 cells. JHIT2e aptamer sodiu retains the ability to specifically bind HepG2 and can deliver fluorescent materials or radionuclides to tumors .
    JHIT2e aptamer sodium
  • HY-N10207
    Penicitide A

    		Endogenous Metabolite Infection Cancer
    Penicitide A is a marine secondary metabolite. Penicitide A shows moderate cytotoxicity against pathogen A. brassicae and the human hepatocellular liver carcinoma (HepG2) cell line .
    Penicitide A
  • HY-175208
    MST3-IN-1

    		Hippo (MST) Caspase Bcl-2 Family Apoptosis Cancer
    MST3-IN-1 is a selective and orally active MST3 inhibitor, with an IC50 of 122.4 nM. MST3-IN-1 shows antiproliferative activity against HepG2 cell. MST3-IN-1 effectively induces apoptosis in HepG2 cells, and halts the cell cycle at the G2/M transition. MST3-IN-1 significantly suppressed tumor growth in HepG2 xenograft mice. MST3-IN-1 can be used for the study of liver cancer .
    MST3-IN-1
  • HY-172225
    [Ru(phen)2(HMPIP)](PF6)2

    		Apoptosis Autophagy Ferroptosis Cancer
    [Ru(phen)2(HMPIP)](PF6)2 (Compound 6A) is an anti-tumor agent. [Ru(phen)2(HMPIP)](PF6)2 can inhibit the proliferation and migration of HepG2 liver cancer cells, and induce apoptosis, autophagy, cell cycle arrest and ferroptosis of HepG2 liver cancer cells. [Ru(phen)2(HMPIP)](PF6)2 exerts its anti-tumor activity by stimulating immune response to increase CD8+ T cells .
    [Ru(phen)2(HMPIP)](PF6)2
  • HY-175174
    Antiproliferative agent-73

    		Others Cancer
    Antiproliferative agent-73 (Compound 7) is an antiproliferative agent. Antiproliferative agent-73 significantly inhibits proliferation of human cancer cells with excellent cytotoxicity. Antiproliferative agent-73 has potent anticancer activity with IC50s of 15.20, 18.18, 20.20 and 13.23  μM for HepG2, MCF-7, HCT-116 and WI38 cells, respectively. Antiproliferative agent-73 can be used for cancers research, such as breast, colorectal and liver cancer .
    Antiproliferative agent-73
  • HY-120607
    Chevalone C

    		Parasite Infection Cancer
    Chevalone C, a meroterpenoid fungal metabolite, shows antimalarial activity with IC50 value of 25.00 μg/mL. Chevalone C has anti-proliferative activity on colon HCT116, liver HepG2 and melanoma A375 cancer cell lines .
    Chevalone C
  • HY-113000
    Cetoleic acid

    		Endogenous Metabolite Cardiovascular Disease
    Cetoleic acid is a long-chain monounsaturated fatty acid found in deep-sea fish. Cetoleic acid can promote the synthesis of ALA in human HepG2 cells and EPA in vitro in salmon liver cells, affecting cholesterol levels in rodents. Cetoleic acid has potential applications in cardiovascular disease research .
    Cetoleic acid
  • HY-142101
    3,4-Didehydroglabridin

    		Others Inflammation/Immunology
    3,4-Didehydroglabridin is a natural product that can be found in licorice. 3,4-Didehydroglabridin exhibits protective activities against carbon tetrachloride-induced HepG2 cells injury. 3,4-Didehydroglabridin has the potential for the research of liver injury .
    3,4-Didehydroglabridin
  • HY-N15535
    Cuneataside E

    		Others Cancer
    Cuneataside E is a phenylpropanoid glycoside compound found in Lespedeza cuneata. Cuneataside E exhibits hepatoprotective activity against the toxicity induced by N-acetyl-p-aminophenol (APAP) in the human hepatocellular carcinoma cell line HepG2. Cuneataside E is promising for research of liver diseases .
    Cuneataside E
  • HY-162580
    SphK2-IN-3

    		SphK Cancer
    SphK2-IN-3 (compound 12q) is a selective active sphingosine kinase-2 inhibitor. SphK2-IN-3 has anti-proliferative activity against various cancer cells, inducing G2 phase arrest and apoptosis in liver cancer cells HepG2 .
    SphK2-IN-3
  • HY-N7905
    Myricetin 3'-glucoside

    		Others Inflammation/Immunology
    Myricetin 3'-glucoside is a glycoside derivative of quercetin. Myricetin 3'-glucoside significantly prevents ethanol-induced hepatotoxicity by reducing hepatic transaminase activity and inflammatory response in HepG2 cells. Myricetin 3'-glucoside has a certain protective effect on alcohol-induced liver injury .
    Myricetin 3'-glucoside
  • HY-128135
    MHY 553

    		PPAR Inflammation/Immunology
    MHY 553 is a PPARα agonist that is effective when taken orally. MHY 553 helps alleviate liver fat accumulation by increasing fatty acid oxidation and reducing inflammation during the aging process. MHY 553 inhibits the accumulation of triglycerides induced by liver X receptor agonists in HepG2 cells. MHY 553 significantly suppresses the expression of inflammatory mRNA in aging rats .
    MHY 553
  • HY-153547
    HSP90-IN-21

    		Parasite Infection Inflammation/Immunology
    HSP90-IN-21 (5e) is an antiplasmodial agent, with IC50 values of 0.04, 0.17 and 2.91 μM against erythrocytic stage of P. falciparum (Pf3D7 and PfDd2 strains), cytotoxicity of human liver hepatocellular carcinoma cell line (HepG2), respectively .
    HSP90-IN-21
  • HY-146350
    TrxR-IN-4

    		TrxR Cancer
    TrxR-IN-4 (Compound 1b) is a potent inhibitor of TrxR. TrxR-IN-4 induces HepG2 cells apoptosis by activating the endoplasmic reticulum stress (ERS). TrxR-IN-4 improves the CCl4-induced liver damage in vivo by down-regulation of TrxR expression and inflammation level .
    TrxR-IN-4
  • HY-164799
    FXR agonist 12

    		FXR Inflammation/Immunology
    FXR agonist 12 (Compound C7) is the orally active agonist for FXR. FXR agonist 12 down-regulates bile acid synthesis-related genes, and up-regulates bile acid transport-related genes in HepG2 cells. FXR agonist 12 improves ANIT-induced cholestasis, ameliorates the liver damage and fibrosis in mouse NASH models .
    FXR agonist 12
  • HY-174424
    NPH16

    		PD-1/PD-L1 Apoptosis Cancer
    NPH16 is an orally active PD-1/PD-L1 inhibitor with an IC50 of 24.4 nM. NPH16 can promote HepG2 cell apoptosis. NPH16 shows excellent in vivo antitumor efficacy and favorable pharmacokinetic properties. NPH16 can be used for the study of liver cancer .
    NPH16
  • HY-172169
    PPARγ-IN-5

    		PPAR Inflammation/Immunology
    PPARγ-IN-5 (Compound A3) is the inhibitor for PPARγ. PPARγ-IN-5 inhibits lipid accumulation in hepatocytes without significant cytotoxicity in HepG2 cell (400 µM). PPARγ-IN-5 can be used in research of non-alcoholic fatty liver disease .
    PPARγ-IN-5
  • HY-175176
    HDAC1/6-IN-3

    		HDAC Apoptosis Pyroptosis Cancer
    HDAC1/6-IN-3 is a potent HDAC inhibitor. HDAC1/6-IN-3 shows excellent inhibitory activities against HDAC1 (IC50 = 1.1 nM) and HDAC6 (IC50 = 2.7 nM). HDAC1/6-IN-3 significantly arrests HepG2 cells at the G0/G1 phase and induces apoptosis and pyroptosis. HDAC1/6-IN-3 exhibits significant antitumor activity in the HepG2 xenograft mode. HDAC1/6-IN-3 can be used for the study of cancers such as liver cancer, lung cancer, colon cancer and breast cancer .
    HDAC1/6-IN-3
  • HY-N3626
    Coronalolide

    		Others Cancer
    Coronalolide is a natural triterpene with anticancer effects. Coronalolide exhibits a broad cytotoxic activity for human breast (BT474), gastric (KATO-3), lung (CHAGO), colon (SW-620), and liver (Hep-G2) cancer cell lines, with IC50 values of 6.59 µg/mL, 5.85 µg/mL, 5.42 µg/mL, 4.98 µg/mL, and 6.41 µg/mL, respectively .
    Coronalolide
  • HY-147552
    HIV-1 inhibitor-35

    		HIV Infection
    HIV-1 inhibitor-35 (compound 74) is a potent HIV-1 inhibitor with EC50s of 80 nM and 70 nM for LTR and CMV in HEK293 cells, respectively. HIV-1 inhibitor-35 has inhibitory activity against liver cancer cell HepG2 with a CC50 of 40 nM. HIV-1 inhibitor-35 can be used as HIV-1 latency reversing agent .
    HIV-1 inhibitor-35
  • HY-N15577
    Antiproliferative agent-69

    		Drug Derivative Cancer
    Antiproliferative agent-69 (Compound 1) is a prenylated kaempferol derivative found in the fresh bud’s fur of Platanus acerifolia. Antiproliferative agent-69 shows significant antiproliferative effects against human breast cancer cells (MCF-7) and human hepatocellular carcinoma cells (Hep-G2) with IC50 values of 38.2 μM and 39.5 μM, respectively. Antiproliferative agent-69 is promising for research of breast cancer and liver cancer .
    Antiproliferative agent-69
  • HY-146398
    AMPK activator 6

    		AMPK Metabolic Disease
    AMPK activator 6 (Compound GC) reduces lipid content and activates the AMPK pathway in HepG2 and 3T3-L1 cells. AMPK activator 6 significantly suppresses the increase in triglyceride (TG) , total cholesterol (TC), low-density lipoprotein-C (LDL-C), and other biochemical indices in blood serum. AMPK activator 6 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome .
    AMPK activator 6
  • HY-157404
    Pim-1/2 kinase inhibitor 2

    		Pim Cancer
    Pim-1/2 kinase inhibitor 2 (compound 5b) is a competitive PIM-1 and PIM-2 kinase inhibitor with IC50s of 1.31 μM and 0.67 μM, respectively. Pim-1/2 kinase inhibitor 2 shows in-vitro low cytotoxicity against normal human lung fibroblast Wi-38 cell line and potent in-vitro anticancer activity against myeloid leukaemia (NFS-60), liver (HepG-2), prostate (PC-3), and colon (Caco-2) cancer cell lines .
    Pim-1/2 kinase inhibitor 2
  • HY-159595
    PCSK9-IN-29

    		LDLR PCSK9 Metabolic Disease Inflammation/Immunology
    PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity .
    PCSK9-IN-29
  • HY-N2078
    Yamogenin

    Neodiosgenin

    		 LXR Reactive Oxygen Species (ROS) Apoptosis Fatty Acid Synthase (FASN) Metabolic Disease
    Yamogenin (Neodiosgenin) is a diastereomer of diosgenin. Yamogenin antagonizes the activation of the liver X receptor (LXR) in luciferase ligand assay. Yamogenin inhibits triacylglyceride (TG) accumulation through the suppression of gene expression of fatty acid synthesis in HepG2 hepatocytes. Yamogenin is a steroidal saponin that can be obtained from plant species with in vitro cytotoxicity, antioxidant, and antimicrobial properties. Yamogenin induces cell death via the extrinsic and intrinsic way of apoptosis. Yamogenin inhibits protein denaturation with an IC50 of 1421.92 μg/mL. Yamogenin can be studied in research on gastric cancer .
    Yamogenin
  • HY-169431
    VEGFR-2/AKT-IN-2

    		VEGFR Akt Caspase Bcl-2 Family Apoptosis Cancer
    VEGFR-2/AKT-IN-2 (Compound 5) is a VEGFR-2/AKT inhibitor (IC50: 0.061 μM for VEGFRin HepG2 cell). VEGFR-2/AKT-IN-2 reduces total and phosphorylated AKT as well as up-regulates BAX and Caspase-3 and down-regulates Bcl-2 in cells, thereby promoting Apoptosis. VEGFR-2/AKT-IN-2 causes cell cycle arrest in S phase. VEGFR-2/AKT-IN-2 inhibits the growth of human liver tumor cells .
    VEGFR-2/AKT-IN-2
  • HY-149523
    Anticancer agent 157

    		Apoptosis NO Synthase Caspase Inflammation/Immunology Cancer
    Anticancer agent 157 (compound 15) is a NO inhibitor (IC50=0.62 μg/mL) with anti-inflammatory and anticancer activities. Anticancer agent 157 can bind to iNOS (inducible NO synthase) and caspase 8, causing nuclear fragmentation and chromatin condensation, inducing apoptosis. Anticancer agent 157 inhibits HT29 colon cancer cells (IC50=2.45 μg/mL), Hep-G2 liver cancer cells (IC50=3.25 μg/mL), and B16-F10 murine melanoma cells (IC50=3.84 μg/mL) .
    Anticancer agent 157
  • HY-168337
    SET-171

    		JNK Pyruvate Kinase
    SET-171 is a JNK (c-Jun N-terminal kinase) inhibitor that exhibits significant anticancer activity and lipid metabolism regulation by inhibiting liver pyruvate kinase (PKL) expression. In anticancer studies, SET-171 shows IC50 values of 8.82 μM and 2.97 μM against HepG2 and Huh7 cell lines, respectively, indicating high cytotoxicity. Additionally, in non-alcoholic fatty liver disease (NAFLD)-related studies, SET-171 significantly reduces triacylglycerol (TAG) levels and inhibits the expression of steatosis-related proteins. SET-171 holds promise for research on hepatocellular carcinoma (HCC) and NAFLD .
    SET-171
  • HY-N2078R
    Yamogenin (Standard)

    Neodiosgenin (Standard)

    		 Reference Standards LXR Apoptosis Fatty Acid Synthase (FASN) Reactive Oxygen Species (ROS) Metabolic Disease
    Yamogenin (Standard) is the analytical standard of Yamogenin. This product is intended for research and analytical applications. Yamogenin (Neodiosgenin) is a diastereomer of diosgenin. Yamogenin antagonizes the activation of the liver X receptor (LXR) in luciferase ligand assay. Yamogenin inhibits triacylglyceride (TG) accumulation through the suppression of gene expression of fatty acid synthesis in HepG2 hepatocytes. Yamogenin is a steroidal saponin that can be obtained from plant species with in vitro cytotoxicity, antioxidant, and antimicrobial properties. Yamogenin induces cell death via the extrinsic and intrinsic way of apoptosis. Yamogenin inhibits protein denaturation with an IC50 of 1421.92 μg/mL. Yamogenin can be studied in research on gastric cancer .
    Yamogenin (Standard)
  • HY-N4314
    Scutellarein tetramethyl ether
    2 Publications Verification

    4',5,6,7-Tetramethoxyflavone

    		 Bacterial COX NO Synthase NF-κB Infection Inflammation/Immunology Cancer
    Scutellarein tetramethyl ether (4',5,6,7-Tetramethoxyflavone) is a bioactive compound extracted from Eupatorium odoratum. Scutellarein tetramethyl ether exhibits anti-inflammatory, antibacterial, pro-coagulant, and anti-tumor activities. Scutellarein tetramethyl ether exerts its anti-inflammatory effects by modulating the NF-κB pathway and regulates bacterial resistance through the inhibition of efflux pumps. Additionally, Scutellarein tetramethyl ether accelerates coagulation time via the endogenous coagulation pathway. Studies have shown that Scutellarein tetramethyl ether can effectively inhibit the growth of the liver cancer cell line HepG2 (IC50= 20.08 μg/mL) .
    Scutellarein tetramethyl ether
  • HY-N4314R
    Scutellarein tetramethyl ether (Standard)

    4',5,6,7-Tetramethoxyflavone (Standard)

    		 Reference Standards Bacterial COX NO Synthase NF-κB Infection Inflammation/Immunology Cancer
    Scutellarein tetramethyl ether (Standard) is the analytical standard of Scutellarein tetramethyl ether. This product is intended for research and analytical applications. Scutellarein tetramethyl ether (4',5,6,7-Tetramethoxyflavone) is a bioactive compound extracted from Eupatorium odoratum. Scutellarein tetramethyl ether exhibits anti-inflammatory, antibacterial, pro-coagulant, and anti-tumor activities. Scutellarein tetramethyl ether exerts its anti-inflammatory effects by modulating the NF-κB pathway and regulates bacterial resistance through the inhibition of efflux pumps. Additionally, Scutellarein tetramethyl ether accelerates coagulation time via the endogenous coagulation pathway. Studies have shown that Scutellarein tetramethyl ether can effectively inhibit the growth of the liver cancer cell line HepG2 (IC50= 20.08 μg/mL) .
    Scutellarein tetramethyl ether (Standard)
  • HY-B0854
    Mancozeb

    		Fungal Keap1-Nrf2 Apoptosis Lactate Dehydrogenase Cytochrome P450 Infection Metabolic Disease Cancer
    Mancozeb is a widely used fungicide that is effective against fungal diseases in most cereals, vegetables, fruits and ornamental plants. In addition, Mancozeb can cause liver damage in mice by activating the Keap1/Nrf2 signaling pathway. Mancozeb upregulates lactate dehydrogenase and cytochrome c to alter cell metabolism and induce cell death. Mancozeb has reproductive toxicity and can induce apoptosis in ovarian cells .
    Mancozeb
  • HY-N0401A
    (Z)-Ligustilide
    4 Publications Verification

    		 Bacterial Estrogen Receptor/ERR FATP Infection Metabolic Disease
    (Z)-Ligustilide is extracted from Ligusticum chuanxiong Hort, has antimicrobial and antifungal activity, exhibits an average antifungal score of 5.6 . (Z)-Ligustilide is orally active, it inhibits the expression of FATP5 and DGAT, inhibits fatty acid uptake and esterification in mice and has potential as therapeutics for nonalcoholic fatty liver disease (NAFLD) . (Z)-Ligustilide is also able to reactivate ERα, has epigenetic regulation, and is used in the study of tamoxifen-resistant breast cancer .
    (Z)-Ligustilide
  • HY-174887
    THR-β agonist 9

    		Thyroid Hormone Receptor AMPK Acetyl-CoA Carboxylase Mitochondrial Metabolism Metabolic Disease
    THR-β agonist 9 is a potent, selective, and His435 mutation-sensitive THR-β (EC50: 3.2 nM) agonist. THR-β agonist 9 has moderate selectivity (approximately 10-fold) and good activation capacity (EC50: 134.2 nM to 515.5 nM) for multiple His435 mutants (H435A, H435Y, and H435R). THR-β agonist 9 has the potential to be used in the study of dyslipidemia, metabolic dysfunction-associated steatohepatitis (MASH), or resistance to thyroid hormone (RTH) .
    THR-β agonist 9
  • HY-146288
    LXR agonist 2

    		LXR Metabolic Disease
    LXR agonist 2 (compound 18rr) is a potent LXR (liver X receptor) agonist. LXR agonist 2 can stabilize NCOA1 (co-activator), leading to LXR agonism .
    LXR agonist 2
  • HY-103697A
    Gardiquimod diTFA

    		Toll-like Receptor (TLR) Cancer
    Gardiquimod diTFA is an imidazoline TLR7/8 agonist. Gardiquimod diTFA inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically activates TLR7 at concentrations below 10 μM.
    Gardiquimod diTFA
  • HY-103697AR
    Gardiquimod diTFA (Standard)

    		Toll-like Receptor (TLR) Reference Standards Cancer
    Gardiquimod (diTFA) (Standard) is the analytical standard of Gardiquimod (diTFA). This product is intended for research and analytical applications. Gardiquimod diTFA is an imidazoline TLR7/8 agonist. Gardiquimod diTFA inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod diTFA specifically activates TLR7 at concentrations below 10 μM.
    Gardiquimod diTFA (Standard)
  • HY-103697R
    Gardiquimod (Standard)

    		Toll-like Receptor (TLR) Reference Standards Cancer
    Gardiquimod (Standard) is the analytical standard of Gardiquimod. This product is intended for research and analytical applications. Gardiquimod is an imidazoline TLR7/8 agonist. Gardiquimod inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod specifically activates TLR7 at concentrations below 10 μM.
    Gardiquimod (Standard)
  • HY-103697B
    Gardiquimod hydrochloride

    		HIV Toll-like Receptor (TLR) Infection Cancer
    Gardiquimod (hydrochloride) is an imidazoline TLR7/8 agonist. Gardiquimod (hydrochloride) inhibits HIV-1 infection of macrophages and activates peripheral blood mononuclear cells (PBMCs). Gardiquimod (hydrochloride) specifically activates TLR7 at concentrations below 10 μM .
    Gardiquimod hydrochloride
  • HY-103697
    Gardiquimod

    		Toll-like Receptor (TLR) Cancer
    Gardiquimod is an imidazoline TLR7/8 agonist. Gardiquimod inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs). Gardiquimod specifically activates TLR7 at concentrations below 10 μM.
    Gardiquimod
  • HY-172157
    HDAC11-IN-2

    		HDAC AMPK Metabolic Disease
    HDAC11-IN-2 (compound B6) is a high selective Histone Deacetylase 11 (HDAC11) inhibitor. HDAC11-IN-2 inhibits HDAC11 and HDAC8 with IC50s of 51.1 ×10 -3 μM and 5 μM, respectively. HDAC11-IN-2 inhibits denovolipogenesis (DNL) and promotes fatty acid oxidation, thus mitigating hepaticlipid accumulation and pathological symptoms in MASLD mice. HDAC11-IN-2 enhances the phosphorylation of AMPKα1 at Thr172 through the inhibition of HDAC11, consequently modulating DNL and fatty acid oxidation in the liver .
    HDAC11-IN-2
  • HY-N6712
    Thiolutin
    3 Publications Verification

    Acetopyrrothin

    		 Antibiotic Bacterial Deubiquitinase NOD-like Receptor (NLR) DNA/RNA Synthesis Pyroptosis HMG-CoA Reductase (HMGCR) Infection Cardiovascular Disease Cancer
    Thiolutin (Acetopyrrothin) is a sulfur-containing antibiotic, which is a potent inhibitor of bacterial and yeast RNA polymerases. Thiolutin can be produced by Streptomyces. Thiolutin inhibits AMSH (IC50 = 4 μM) and Rpn11 (IC50 = 0.53 μM). Thiolutin is a dual inhibitor of BRCC36 and the NLRP3 inflammasome, exhibiting anti-inflammatory effects. Thiolutin effectively suppresses the interaction between BRCC36 and HMGCR, leading to the inhibition of HCC growth. Thiolutin attenuates pyroptosis and NLRP3 inflammasome activation. Thiolutin markedly alleviates renal injury and inflammatory process in IgAN. Thiolutin is an anti-angiogenic compound which can ease Doxorubicin-induced cardiotoxicity (DOXIC) [1][2][3][4][5].
    Thiolutin
  • HY-N6712R
    Thiolutin (Standard)

    Acetopyrrothin (Standard)

    		 Reference Standards Antibiotic Bacterial Deubiquitinase NOD-like Receptor (NLR) DNA/RNA Synthesis Pyroptosis HMG-CoA Reductase (HMGCR) Cardiovascular Disease Inflammation/Immunology Cancer
    Thromycin (Standard) is the analytical standard of thromycin (HY-N6712). Thiolutin (Acetopyrrothin) is a sulfur-containing antibiotic, which is a potent inhibitor of bacterial and yeast RNA polymerases. Thiolutin can be produced by Streptomyces. Thiolutin inhibits AMSH (IC50 = 4 μM) and Rpn11 (IC50 = 0.53 μM). Thiolutin is a dual inhibitor of BRCC36 and the NLRP3 inflammasome, exhibiting anti-inflammatory effects. Thiolutin effectively suppresses the interaction between BRCC36 and HMGCR, leading to the inhibition of HCC growth. Thiolutin attenuates pyroptosis and NLRP3 inflammasome activation. Thiolutin markedly alleviates renal injury and inflammatory process in IgAN. Thiolutin is an anti-angiogenic compound which can ease Doxorubicin-induced cardiotoxicity (DOXIC) [1][2][3][4][5].
    Thiolutin (Standard)
  • HY-175035
    HK-2-IN-1

    		Hexokinase Inflammation/Immunology Cancer
    HK-2-IN-1 is a Hexokinase 2 (HK-2) inhibitor. HK-2-IN-1 exhibits a non-activating effect on human recombinant HK-2 enzyme. HK-2-IN-1 has anti-tumor activity, affecting immune cells in the tumor microenvironment. HK-2-IN-1 has immunomodulatory effects and is potentially useful in the study of cancers such as colon cancer, liver cancer, and breast cancer .
    HK-2-IN-1
  • HY-N0316
    Mollugin
    2 Publications Verification

    		 JAK NF-κB Reactive Oxygen Species (ROS) Apoptosis VEGFR c-Myc Cancer
    Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway .
    Mollugin
  • HY-N0316R
    Mollugin (Standard)

    		JAK Reference Standards NF-κB Reactive Oxygen Species (ROS) Apoptosis VEGFR c-Myc Cancer
    Mollugin (Standard) is the analytical standard of Mollugin. This product is intended for research and analytical applications. Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway .
    Mollugin (Standard)
  • HY-144725
    HDAC1/6-IN-1

    		HDAC Apoptosis Cancer
    HDAC1/6-IN-1 (compound D7) is a potent multitarget inhibitor of GLP, HDAC6 and HDAC1, with IC50 values of 1.3, 13, and 89 nM, respectively. HDAC1/6-IN-1 can inhibit the methylation and deacetylation of H3K9 on protein level. HDAC1/6-IN-1 induces cancer cell apoptosis, G0/G1 cell cycle arrest, and blocks migration and invasion .
    HDAC1/6-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: